Bernstein Upgrades Amgen (AMGN) to Outperform
More News related to AMGN
- Amgen (AMGN) Announces Cancer Survival Results when Faced with Vectibix in Combination with FOLFOX
- Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer
- Call for Applications: The Amgen Award for Science Teaching Excellence
- Trading Outlook for Avanir Pharmaceuticals Inc. Issued by InvestorSoup.com
- Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Primary Efficacy Endpoints
Sanford C. Bernstein upgrades Amgen (Nasdaq: AMGN) from Market Perform to Outperform.
For more analyst ratings on AMGN click here.
Amgen Inc., a biotechnology company, engages in the discovery, development, manufacture, and marketing of human therapeutics based on advances in cellular and molecular biology.
Related Categories
UpgradesStocks Mentioned
+0.64Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
